Compounded Semaglutide in 2026: Legal Status & Best Providers

The current state of compounded GLP-1 medications

To understand what’s legal in 2026, it helps to understand what changed. Between 2022 and early 2026, the FDA officially classified semaglutide and tirzepatide as drugs in shortage. Under federal law, when an FDA-approved drug is on the official shortage list, both 503A traditional compounding pharmacies and 503B outsourcing facilities are permitted to compound copies. That carve-out enabled the rapid growth of compounded GLP-1 telehealth between 2023 and 2025.

In February 2026, the FDA formally declared the shortages resolved.[2] That declaration triggered a regulatory shift. 503B outsourcing facilities were given a transition period to wind down general compounding of semaglutide. By the end of the wind-down period, 503B production of compounded semaglutide for routine distribution was no longer permitted under the shortage exception.

503A pharmacies operate under different rules. They compound for individual patients, one prescription at a time, in response to specific clinical needs documented by the prescriber. The 503A pathway has not been broadly closed, but the bar for what qualifies as a documented clinical need has been raised through enforcement guidance and warning letters issued in March and April 2026.

503A vs 503B: why the distinction matters

The Drug Quality and Security Act of 2013 established two categories of compounding pharmacy in U.S. federal law. The distinction matters because they operate under different rules and the February 2026 action affected them differently.

503A pharmacies

Traditional compounding pharmacies that prepare medications for individual patients based on individual prescriptions. Each preparation is tied to a specific patient with a specific prescription from a specific licensed provider. Regulation is primarily by the patient’s state board of pharmacy. Most telehealth platforms still offering compounded GLP-1 in 2026 partner with 503A pharmacies.

503B outsourcing facilities

Larger-scale compounders that register with the FDA to produce medications in bulk for distribution to healthcare facilities. Can produce medications in batches without patient-specific prescriptions. Subject to FDA inspection and cGMP standards. 503B production of compounded semaglutide for general distribution was specifically affected by the February 2026 action.

What this means for you as a patient: when choosing a telehealth provider for compounded GLP-1 medication in 2026, you want a provider that partners with a properly licensed 503A pharmacy and that documents clinical justification for the compounded prescription. Providers operating outside this framework face increasing regulatory risk that could affect your continuity of care.

What to look for in a compliant provider

Five things we look for when evaluating a telehealth provider in this category:

1. Discloses pharmacy partner status. The provider should be able to tell you, on request, whether your medication is prepared by a 503A or 503B facility, what state the pharmacy is licensed in, and what accreditations the pharmacy holds.
2. Builds clinical justification into intake. Reputable providers ask intake questions that document why compounded medication is clinically appropriate for you specifically, rather than treating every patient as a generic candidate.
3. Has a transition plan. If the regulatory environment changes, your provider should have a clear pathway for patients to transition to brand-name, manufacturer-direct, or alternative therapies without abrupt discontinuation.
4. Updates patients on regulatory changes. Active, transparent communication when FDA guidance changes is a sign of an operator that’s built for the long term rather than the moment.
5. Provides ongoing clinical support. Provider follow-ups, dose-progression management, side-effect support — not just a “fill and ship” transaction.

How the major providers compare

Across the major telehealth platforms still offering compounded GLP-1 in 2026:

What current patients should do

If you’re currently using a compounded GLP-1 medication, the most important guidance is straightforward:

• Don’t stop abruptly. Stopping a GLP-1 medication without medical guidance can result in rapid weight regain and rebound effects. If you’re considering discontinuation, talk to your provider about a structured plan.
• Verify your pharmacy’s status. Confirm that the pharmacy preparing your medication is a properly licensed 503A facility. Reputable providers will tell you this on request. If a provider won’t disclose this, that’s a meaningful warning sign.
• Confirm clinical justification is documented. Make sure your medical record clearly documents why compounded prescription is appropriate for you specifically. If the clinical reason no longer exists, work with your provider to transition to an FDA-approved alternative.
• Have a contingency plan. Understand what your transition pathway looks like if your current option becomes unavailable — whether that’s a different compounded dose, a brand-name product, or alternative therapy entirely.

Alternatives if your option becomes unavailable

If a clinical or regulatory change makes your current compounded medication unavailable, you have several pathways to consider with your provider:

• Brand-name semaglutide or tirzepatide — Wegovy, Zepbound, Ozempic, or Mounjaro. The active ingredient is identical.
• Direct-from-manufacturer programs — LillyDirect (Zepbound) and NovoCare Pharmacy (Wegovy) offer brand-name medication at $349–$499 per month for cash-pay patients.
• Lifestyle and behavioral programs — Structured weight-management programs that combine nutrition counseling, behavioral coaching, and physical activity. Often covered by insurance even when GLP-1 medications are not.
• Other prescription medications — FDA-approved oral medications for weight loss including phentermine, topiramate-naltrexone combinations, and orlistat. Different mechanisms; not equivalent, but options worth discussing.

What you should not do: seek out gray-market or unregulated sources of semaglutide. Research-chemical websites, international pharmacies of unclear provenance, and peer-to-peer markets carry significant risks of contamination, mislabeling, and counterfeit medications. The cost savings are not worth the safety risk.

Frequently asked questions

Closing perspective

The compounded medication category is one of the most regulatorily active areas of telehealth in 2026. That makes it tempting to choose a provider based on price alone — but in this category specifically, price is the wrong primary variable. Pharmacy compliance, clinical justification practices, and the operator’s regulatory posture matter more, because they determine whether your protocol can continue if the rules shift.

The good news is that compliant operators exist, and they’re increasingly easy to identify because the differences are visible: do they disclose pharmacy partners on request? Does their intake form ask the questions that document clinical justification? Do they communicate proactively when FDA guidance changes? An operator that answers yes to all three is the operator most likely to be there in 2027 with your prescription continuing without interruption.

Across the providers we reviewed for this guide, HermanRx scored most consistently across those three regulatory-compliance markers. The provider’s pricing also remains competitive — but the regulatory posture is why it earns our editor’s pick in this specific category, where regulatory posture is the variable that matters most.